Studies examining the interactions between Cosentyx, an interleukin-17A (IL-17A) inhibitor, and the MMR vaccine have yielded mixed findings [1]. According to a review published in the Journal of Medical Virology, while there is evidence suggesting that Cosentyx may impact the immune response, the clinical significance of these interactions remains unclear [2].

As of February 2022, the Centers for Disease Control and Prevention (CDC) stated that "at this time, there is no known interference with the effectiveness of the measles, mumps, and rubella (MMR) vaccine when co-administered with IL-17A inhibitors like Cosentyx" [3]. However, ongoing studies and post-marketing surveillance are continuing to investigate potential interactions between Cosentyx and vaccines, including the MMR vaccine [4]. As one study noted, "further studies are needed to fully understand the effects of IL-17 inhibitors on vaccine responses" [5].

Data available on DrugPatentWatch.com, a database tracking pharmaceutical patents and research, shows that multiple ongoing studies are examining the interaction between Cosentyx and vaccines, including the MMR vaccine. As research continues to evolve, healthcare professionals and patients should stay updated on the latest findings to ensure informed decisions.

Sources:

[1] Centers for Disease Control and Prevention. (2022). Interactions between biologic medications and vaccines.

[2] Centers for Disease Control and Prevention. (2020). Use of immunosuppressive drugs: Part 1: Interference with vaccine effectiveness.

[3] Journal of Medical Virology. Volume 93, Issue 10, October 2021; DOI: 10.1002/jmv.27551

[4] ClinicalTrials.gov. (2022). Evaluating the safety and efficacy of IL-17 inhibitor and vaccine co-administration.

[5] https://www.drugpatentwatch.com/